MX375256B - Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms). - Google Patents
Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).Info
- Publication number
- MX375256B MX375256B MX2015000572A MX2015000572A MX375256B MX 375256 B MX375256 B MX 375256B MX 2015000572 A MX2015000572 A MX 2015000572A MX 2015000572 A MX2015000572 A MX 2015000572A MX 375256 B MX375256 B MX 375256B
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- treating
- subject
- subject suffering
- positive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/02—Carbamic acids; Salts of carbamic acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrotherapy Devices (AREA)
Abstract
Esta invención se refiere al tratamiento del cáncer de mama positivo a receptor de andrógeno en un sujeto, por ejemplo una mujer. Por consiguiente, esta invención proporciona métodos para: a) tratar a un sujeto que padece cáncer de mama; b) tratar a un sujeto que padece cáncer de mama metastásico; c) tratar a un sujeto que padece cáncer de mama refractario; d) tratar a un sujeto que padece cáncer de mama positivo a AR; e) tratar a un sujeto que padece cáncer de mama refractario positivo a AR; f) tratar a un sujeto que padece cáncer de mama metastásico positivo para AR; g) tratar a un sujeto que padece cáncer de mama positivo a AR y positivo a ER; h) tratar a un sujeto que padece cáncer de mama triple negativo; i) tratar a un sujeto que padece cáncer mama avanzado; j) tratar a un sujeto que padece cáncer de mama que ha fallado a tratamientos con SERM (tamixifeno, toromifeno), un inhibidor de aromatasa, trastuzumab (Herceptin, ado-trastuzumab emtansina), pertuzumab (Perjeta), lapatinib, exemestano (Aromasin), bevacizumab (Avastin) y/o fulvestrant; k) tratar, prevenir, suprimir o inhibir metástasis en un sujeto que padece cáncer de mama; 1) prolongar la supervivencia de un sujeto con cáncer de mama; y/o prolongar la supervivencia libre de progresión de un sujeto con cáncer de mama; que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto modulador de receptor de andrógeno selectivo (SARM), que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto SARM de esta invención.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671366P | 2012-07-13 | 2012-07-13 | |
| US201261726274P | 2012-11-14 | 2012-11-14 | |
| PCT/US2013/029667 WO2014011220A2 (en) | 2012-07-13 | 2013-03-07 | A method of treating androgen receptor (ar)-positive breast cancers with selective androgen receptor modulator (sarms) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015000572A MX2015000572A (es) | 2015-09-23 |
| MX375256B true MX375256B (es) | 2025-03-06 |
Family
ID=49914508
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015000572A MX375256B (es) | 2012-07-13 | 2013-03-07 | Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms). |
| MX2020009725A MX2020009725A (es) | 2012-07-13 | 2015-01-13 | Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009725A MX2020009725A (es) | 2012-07-13 | 2015-01-13 | Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms). |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9604916B2 (es) |
| EP (2) | EP3733170A1 (es) |
| JP (3) | JP6226978B2 (es) |
| KR (2) | KR102122941B1 (es) |
| CN (3) | CN108143728A (es) |
| AU (3) | AU2013203600C1 (es) |
| CA (1) | CA2879049C (es) |
| CY (1) | CY1123542T1 (es) |
| DK (1) | DK2872482T3 (es) |
| ES (1) | ES2818915T3 (es) |
| HR (1) | HRP20201463T1 (es) |
| HU (1) | HUE052574T2 (es) |
| IL (1) | IL236681B (es) |
| IN (1) | IN2015DN01046A (es) |
| LT (1) | LT2872482T (es) |
| MX (2) | MX375256B (es) |
| PL (1) | PL2872482T3 (es) |
| PT (1) | PT2872482T (es) |
| RU (2) | RU2648959C2 (es) |
| WO (1) | WO2014011220A2 (es) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
| CA2626337C (en) | 2005-10-19 | 2015-12-29 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
| US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| EP3733170A1 (en) | 2012-07-13 | 2020-11-04 | Oncternal Therapeutics, Inc. | A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US12685719B2 (en) | 2012-07-13 | 2026-07-21 | University Of Tennessee Research Foundation | Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors |
| JP5958483B2 (ja) * | 2013-07-31 | 2016-08-02 | 株式会社村田製作所 | 電力増幅モジュール |
| KR20190077607A (ko) * | 2014-10-16 | 2019-07-03 | 지티엑스, 인코포레이티드 | Sarm을 이용하는 비뇨기 장애의 치료 방법 |
| CA2965372C (en) | 2014-10-22 | 2023-09-05 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| SI4197530T1 (sl) * | 2015-04-16 | 2026-03-31 | Novartis Ag | Tableta ribocikliba |
| US10093613B2 (en) | 2015-04-21 | 2018-10-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10865184B2 (en) | 2015-04-21 | 2020-12-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
| CA2983426C (en) | 2015-04-21 | 2023-10-17 | Gtx, Inc. | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| US10017471B2 (en) | 2015-04-21 | 2018-07-10 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| RU2689988C2 (ru) * | 2015-04-21 | 2019-05-30 | Джи Ти Икс, ИНК. | Селективные лиганды-разрушители андрогенных рецепторов (sard) и способы их применения |
| US10035763B2 (en) | 2015-04-21 | 2018-07-31 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10806720B2 (en) | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US9834507B2 (en) | 2015-04-21 | 2017-12-05 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| CA3002562A1 (en) * | 2015-10-22 | 2017-04-27 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| KR20220071293A (ko) | 2016-04-01 | 2022-05-31 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| US11230523B2 (en) | 2016-06-10 | 2022-01-25 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10806719B2 (en) | 2016-06-10 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| AU2017278314B2 (en) * | 2016-06-10 | 2022-06-30 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| EP3645001B1 (en) * | 2017-06-29 | 2024-07-03 | G1 Therapeutics, Inc. | Morphic forms of git38 and methods of manufacture thereof |
| BR112020023136A2 (pt) | 2018-05-14 | 2021-02-09 | Nuvation Bio Inc. | compostos de alvo de receptor de hormônio nuclear anticâncer |
| WO2019226991A1 (en) | 2018-05-25 | 2019-11-28 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| US12202815B2 (en) | 2018-09-05 | 2025-01-21 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| CN109761778A (zh) * | 2018-12-10 | 2019-05-17 | 石家庄市度智医药科技有限公司 | 一种合成光学活性α-羟基丙酰胺衍生物的方法 |
| US12109179B2 (en) | 2019-03-28 | 2024-10-08 | Essa Pharma Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| WO2020198710A1 (en) * | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| WO2020205608A1 (en) * | 2019-03-29 | 2020-10-08 | Emory University | Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto |
| CN113811333B (zh) * | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
| EP3976577A4 (en) * | 2019-05-29 | 2023-06-28 | University of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| CN114599369B (zh) | 2019-06-03 | 2026-02-10 | 哈瓦赫治疗有限公司 | 用于递送雄激素剂和芳香酶抑制剂的药物制剂和系统以及使用方法 |
| JP2022543832A (ja) | 2019-08-06 | 2022-10-14 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 変異体を治療するためのエストロゲン受容体調節剤 |
| IL295841A (en) * | 2020-02-25 | 2022-10-01 | Univ Tennessee Res Found | and methods for their use (sard) selective androgen receptor cleaving ligands |
| EP4135675A4 (en) | 2020-04-17 | 2024-04-10 | Essa Pharma, Inc. | SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF |
| US20210330653A1 (en) * | 2020-04-24 | 2021-10-28 | Astrazeneca Ab | Dosage Regimen for the Treatment of Cancer |
| BR112023014247A2 (pt) * | 2021-01-15 | 2023-10-03 | Univ Tennessee Res Found | Composições farmacêuticas para tratar cânceres de mama e métodos de usos destas |
| US20230172897A1 (en) * | 2021-12-02 | 2023-06-08 | Veru, Inc. | Methods of treating breast cancers with selective androgen receptor modulators and additional therapeutic agents |
| WO2023172891A2 (en) * | 2022-03-07 | 2023-09-14 | Baylor College Of Medicine | Biomarkers for combination therapy for er+ breast cancer |
| CA3251059A1 (en) | 2022-05-02 | 2023-11-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions, systems and methods for modulating a target gene |
| WO2023244059A1 (en) * | 2022-06-15 | 2023-12-21 | Ildong Pharmaceutical Co., Ltd. | Methods of treating cancer using dual androgen receptor and pde5 inhibitor compounds |
| EP4637929A1 (en) * | 2022-12-21 | 2025-10-29 | Duke University | Coadministration of estrogen with estrogen receptor modulator or degrader or er targeted protac for the treatment of estrogen responsive cancers |
| WO2025208260A1 (zh) * | 2024-04-01 | 2025-10-09 | 北京脑科学与类脑研究所 | 丙酰胺类雄激素受体拮抗剂及其制备方法和用途 |
Family Cites Families (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3256096A (en) | 1961-08-11 | 1966-06-14 | Organic Nutrients Inc | Anabolic stimulator as a poultry feed supplement |
| US3239345A (en) | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
| US3949085A (en) | 1970-05-27 | 1976-04-06 | Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt | Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same |
| US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| GB1360001A (en) | 1971-06-16 | 1974-07-17 | Scherico Ltd | Pharmaceutical compositions comprising substituted anilides |
| US3875229A (en) | 1972-11-24 | 1975-04-01 | Schering Corp | Substituted carboxanilides |
| US3865801A (en) | 1973-06-15 | 1975-02-11 | Atomic Energy Commission | Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol |
| US3946109A (en) | 1973-08-08 | 1976-03-23 | Ernst Kolb | Animal feed composition containing certain vitamin combinations |
| US4036979A (en) | 1974-01-25 | 1977-07-19 | American Cyanamid Company | Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate |
| US4211781A (en) | 1974-09-23 | 1980-07-08 | Pfizer Inc. | Process for the preparation of dustless quinoxaline-1,4-dioxide animal feed supplement premixes |
| US3991750A (en) | 1975-04-28 | 1976-11-16 | Syntex Corporation | Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals |
| JPS6044294B2 (ja) | 1976-04-15 | 1985-10-02 | 帝国臓器製薬株式会社 | アニリド誘導体 |
| US4139638A (en) | 1976-09-23 | 1979-02-13 | Schering Corporation | Methods for the treatment of hirsutism |
| DE2862100D1 (en) | 1977-10-12 | 1983-01-05 | Ici Plc | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them |
| US4191775A (en) | 1977-12-15 | 1980-03-04 | Imperial Chemical Industries Limited | Amide derivatives |
| US4447421A (en) | 1980-05-08 | 1984-05-08 | American Cyanamid Company | Process for the preparation of medicated animal feed supplement |
| NZ197008A (en) | 1980-05-22 | 1984-10-19 | Ici Ltd | Acylanilide derivatives and pharmaceutical compositions |
| JPS57171904A (en) | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
| DE3372965D1 (en) | 1982-07-23 | 1987-09-17 | Ici Plc | Amide derivatives |
| KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| FR2576025B1 (fr) | 1985-01-14 | 1987-01-23 | Roussel Uclaf | Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant |
| US4670249A (en) | 1985-04-12 | 1987-06-02 | International Minerals & Chemical Corp. | Growth-promoting compositions |
| US4837004A (en) | 1985-10-18 | 1989-06-06 | Eastman Kodak Company | Rumen-stable pellets |
| US4904473A (en) | 1986-06-23 | 1990-02-27 | International Minerals & Chemical Corp. | Ruminant feed antacid containing potassium, sodium and chlorine |
| GB8617652D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Acylanilide derivatives |
| GB8617653D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
| US4849447A (en) | 1987-10-13 | 1989-07-18 | Pitman-Moore, Inc. | Zearalanol derivatives with anabolic activity |
| AU637316B2 (en) | 1988-01-28 | 1993-05-27 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
| AU628322B2 (en) | 1988-01-28 | 1992-09-17 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
| US4977288A (en) | 1988-01-29 | 1990-12-11 | President And Fellows Of Harvard College | M-aminophenyltrialkylstannane |
| US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| US5179080A (en) | 1989-08-31 | 1993-01-12 | Clinical Homecare, Corp. | Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease |
| AU646822B2 (en) | 1989-10-13 | 1994-03-10 | Kirin-Amgen Inc. | Erythropoietin isoforms |
| US5030657A (en) | 1989-10-23 | 1991-07-09 | University Of Georgia Research Foundation, Inc. | L-carnitine supplemented catfish diet |
| US5288496A (en) | 1990-05-15 | 1994-02-22 | Stolle Research & Development Corporation | Growth promoters for animals |
| US5663146A (en) | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
| CA2181358A1 (en) | 1994-01-21 | 1995-07-27 | Nancy M. Gray | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
| US5609849A (en) | 1994-03-11 | 1997-03-11 | The Trustees Of The University Of Pennsylvania | Serotonin (5-HT1A) receptor ligands and imaging agents |
| DK0683172T3 (da) | 1994-05-19 | 1998-03-30 | Akzo Nobel Nv | 11,21-bisphenyl-19-norpregnanderivater |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| WO1998005962A1 (en) | 1996-08-02 | 1998-02-12 | Panvera Corporation | A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization |
| US20050038110A1 (en) | 2000-08-24 | 2005-02-17 | Steiner Mitchell S. | Selective androgen receptor modulators and methods of use thereof |
| US20090264534A1 (en) | 1996-11-27 | 2009-10-22 | Dalton James T | Selective androgen receptor modulators |
| US7205437B2 (en) | 1996-11-27 | 2007-04-17 | University Of Tennessee Research Foundation | Selective androgen receptor modulators |
| US7759520B2 (en) | 1996-11-27 | 2010-07-20 | University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
| US7518013B2 (en) | 2000-08-24 | 2009-04-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators |
| US6071957A (en) | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
| US6995284B2 (en) | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
| US6569896B2 (en) | 2000-08-24 | 2003-05-27 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
| WO1998027986A1 (en) | 1996-12-24 | 1998-07-02 | Zymogenetics, Inc. | Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| AU7604798A (en) | 1997-05-30 | 1998-12-30 | University Of Tennessee Research Corporation, The | Non-steroidal agonist compounds and their use in male hormone therapy |
| WO1998055153A1 (en) | 1997-06-04 | 1998-12-10 | The University Of Tennessee Research Corporation | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
| EP0903146A1 (en) | 1997-09-23 | 1999-03-24 | Applied Research Systems ARS Holdings N.V. | 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid |
| US6022137A (en) | 1998-04-29 | 2000-02-08 | Buckeye Feed Mills, Inc. | Conditioner for processing raw grain composition to produce pelletized feed |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| AU3103800A (en) | 1998-12-23 | 2000-07-31 | G.D. Searle Llc | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications |
| HK1046139B (zh) | 1999-03-29 | 2004-12-10 | 霍夫曼-拉罗奇有限公司 | 葡糖激酶活化剂 |
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| AU7558900A (en) | 1999-10-14 | 2001-04-23 | Kaken Pharmaceutical Co., Ltd. | Tetrahydroquinoline derivatives |
| JP2003511467A (ja) | 1999-10-14 | 2003-03-25 | ブリストル−マイヤーズ スクイブ カンパニー | アンドロゲンレセプターリガンド結合ドメインの結晶構造 |
| PL354620A1 (en) | 1999-10-19 | 2004-02-09 | Nobex Corporation | Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof |
| NZ518552A (en) | 1999-10-27 | 2003-10-31 | Nobex Corp | Resolution of intermediates in the synthesis of substantially pure bicalutamide |
| US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| AU2625201A (en) | 2000-01-03 | 2001-07-16 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Glycogen synthase kinase-3 inhibitors |
| US6441197B1 (en) | 2000-01-20 | 2002-08-27 | Daiichi Pure Chemicals Co., Ltd. | Diaminofluorescein derivative |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US7713989B2 (en) | 2000-04-27 | 2010-05-11 | Dow Robert L | Glucocorticoid receptor modulators |
| HUP0303172A3 (en) | 2000-06-28 | 2006-05-29 | Bristol Myers Squibb Co | Selective androgen receptor modulators and methods for their identification, desing and use |
| US7645898B2 (en) | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
| US8008348B2 (en) | 2001-12-06 | 2011-08-30 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
| US20070173546A1 (en) | 2000-08-24 | 2007-07-26 | Dalton James T | Selective androgen receptor modulators and method of use thereof |
| US20060019931A1 (en) | 2003-10-14 | 2006-01-26 | Dalton James T | Treating bone-related disorders with selective androgen receptor modulators |
| US6998500B2 (en) | 2000-08-24 | 2006-02-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| US7026500B2 (en) | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| US6838484B2 (en) | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
| US20020173495A1 (en) | 2000-08-24 | 2002-11-21 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
| IL154425A0 (en) | 2000-08-24 | 2003-09-17 | Univ Tennessee Res H Corp | Selective androgen receptor modulators and methods of use thereof |
| US20040260108A1 (en) | 2001-06-25 | 2004-12-23 | Dalton James T. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| US7919647B2 (en) | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| US7855229B2 (en) | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
| US8445534B2 (en) | 2000-08-24 | 2013-05-21 | University Of Tennessee Research Foundation | Treating androgen decline in aging male (ADAM)-associated conditions with SARMs |
| US20030232792A1 (en) | 2000-08-24 | 2003-12-18 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
| US20030229099A1 (en) | 2000-08-30 | 2003-12-11 | Zhu Hugh Y. | Novel farnesyl protein transferase inhibitors as antitumor agents |
| US6777446B2 (en) | 2000-09-05 | 2004-08-17 | Tularik, Inc. | FXR modulators |
| WO2002022585A1 (en) | 2000-09-14 | 2002-03-21 | Kaken Pharmaceutical Co., Ltd. | Tetrahydroquinoline compounds |
| SE0102300D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
| WO2003015820A1 (en) | 2001-08-10 | 2003-02-27 | Takeda Chemical Industries, Ltd. | GnRH AGONIST COMBINATION DRUGS |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| US20060004042A1 (en) | 2001-08-23 | 2006-01-05 | Dalton James T | Formulations comprising selective androgen receptor modulators |
| MXPA04005112A (es) | 2001-11-29 | 2005-04-29 | Gtx Inc | Prevencion y tratamiento de osteoporosis inducida por privacion de androgeno. |
| PT1463497E (pt) | 2001-12-06 | 2011-12-20 | Gtx Inc | Tratamento do desgaste muscular com moduladores selectivos do receptor de androgénios |
| US20070066568A1 (en) | 2005-08-31 | 2007-03-22 | Dalton James T | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators |
| US20070161608A1 (en) | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
| US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
| WO2003065983A2 (en) | 2002-02-01 | 2003-08-14 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| CA2689080C (en) | 2002-02-07 | 2011-07-05 | University Of Tennessee Research Foundation | Treating benign prostate hyperplasia with sarms |
| WO2003074449A2 (en) | 2002-02-28 | 2003-09-12 | University Of Tennessee Research Foundation | Multi-substitued selective androgen receptor modulators and methods of use thereof |
| US7772433B2 (en) | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
| JP5113979B2 (ja) | 2002-02-28 | 2013-01-09 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法 |
| US7803970B2 (en) | 2002-02-28 | 2010-09-28 | University Of Tennessee Research Foundation | Multi-substitued selective androgen receptor modulators and methods of use thereof |
| HRP20040818A2 (en) | 2002-02-28 | 2005-02-28 | University Of Tennessee Research Foundation | Haloacetamide and azide substituted compounds and methods of use thereof |
| WO2003074450A2 (en) | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
| NZ534946A (en) | 2002-03-13 | 2007-05-31 | Merck & Co Inc | Fluorinated 4-azasteroid derivatives as androgen receptor modulators |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| AU2003241583B2 (en) | 2002-06-17 | 2009-05-21 | University Of Tennessee Research Foundation | N-bridged selective androgen receptor modulators and methods of use thereof |
| EP1398029A1 (en) | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
| US20040265916A1 (en) | 2002-10-15 | 2004-12-30 | Dalton James T. | Method for detecting selective androgen receptor modulators |
| JP2006518328A (ja) | 2002-10-15 | 2006-08-10 | ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション | 複素環選択的アンドロゲン受容体調節剤及びその使用方法 |
| AU2003287075A1 (en) | 2002-10-15 | 2004-05-04 | Gtx, Inc. | Treating obesity with selective androgen receptor modulators |
| US20040197928A1 (en) | 2002-10-15 | 2004-10-07 | Dalton James T. | Method for detecting selective androgen receptor modulators |
| EP1562594A4 (en) | 2002-10-15 | 2008-12-17 | Univ Tennessee Res Foundation | SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH METHYLENE BRIDGES AND METHOD OF USE THEREOF |
| US20040087810A1 (en) | 2002-10-23 | 2004-05-06 | Dalton James T. | Irreversible selective androgen receptor modulators and methods of use thereof |
| US20140011774A1 (en) | 2002-12-05 | 2014-01-09 | University Of Tennessee Research Foundation | Selective androgen receptor modulators |
| US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US7199110B2 (en) | 2002-12-30 | 2007-04-03 | Purdue Research Foundation | Method of treatment for spinal cord injury |
| EP2457892A1 (en) | 2003-01-13 | 2012-05-30 | University of Tennessee Research Foundation | Large-scale synthesis of selective androgen receptor modulators |
| EP1594490A4 (en) * | 2003-01-22 | 2006-03-22 | Gtx Inc | TREATMENT OF WOMEN ANDROGEN DISEASE ASSOCIATED DISORDERS (ADIF) USING ANDROGENIC RECEPTOR MODULATORS (SARM) |
| EP1594489A2 (en) | 2003-01-22 | 2005-11-16 | GTX, Inc. | A method of treating breast cancer with androgen receptor antagonists |
| US20040167103A1 (en) * | 2003-02-24 | 2004-08-26 | Dalton James T. | Haloacetamide and azide substituted compounds and methods of use thereof |
| GB0308335D0 (en) | 2003-04-10 | 2003-05-14 | Novartis Ag | Organic compounds |
| CN1325506C (zh) | 2003-05-15 | 2007-07-11 | 中国科学院上海药物研究所 | 骨重吸收抑制剂阿伦膦酸及生理可接受的盐和它的制备 |
| EP1643971A2 (en) | 2003-05-22 | 2006-04-12 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
| FI20030958A0 (fi) | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
| EP1670483A4 (en) | 2003-09-10 | 2010-02-17 | Merck & Co Inc | 17-heterocyclic 4-azasteroid derivatives as androgen receptor modules |
| HRP20070527T3 (en) | 2003-09-12 | 2007-12-31 | Laboratoires Serono Sa | Benzothiazole derivatives for the treatment of diabetes |
| TW200523235A (en) | 2003-10-15 | 2005-07-16 | Gtx Inc | Anti-cancer compounds and methods of use thereof |
| US20050137172A1 (en) | 2003-10-15 | 2005-06-23 | Dalton James T. | Haloacetamide and azide substituted compounds and methods of use thereof |
| GB0325402D0 (en) | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
| AU2004305061A1 (en) | 2003-12-16 | 2005-07-07 | Gtx, Inc. | Prodrugs of selective androgen receptor modulators and methods of use thereof |
| TW200530181A (en) | 2004-01-13 | 2005-09-16 | Bristol Myers Squibb Co | Heterocyclic compounds useful as growth hormone secretagogues |
| MXPA06012683A (es) | 2004-05-03 | 2007-01-16 | Hoffmann La Roche | Derivados de indolilo como moduladores de receptor x del higado. |
| US20130034562A1 (en) | 2004-06-07 | 2013-02-07 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
| DK2289872T3 (en) | 2004-06-07 | 2017-10-09 | Univ Tennessee Res Found | Medical use of a selective androgen receptor modulator |
| US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
| EA200700262A1 (ru) | 2004-07-14 | 2007-08-31 | Янссен Фармацевтика Н.В. | Арилидены для лечения заболеваний, опосредуемых эстроген-родственным рецепторам альфа |
| US7825229B2 (en) | 2005-03-25 | 2010-11-02 | Rosetta Genomics Ltd. | Lung cancer-related nucleic acids |
| EP1951706A1 (en) | 2005-11-01 | 2008-08-06 | Janssen Pharmaceutica N.V. | Dihydroisoindolones as allosteric modulators of glucokinase |
| CA2627892A1 (en) | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted dihydroisoindolones as allosteric modulators of glucokinase |
| CA2824517A1 (en) | 2005-11-28 | 2007-05-31 | Gtx, Inc. | Nuclear receptor binding agents |
| US8158828B2 (en) | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
| CA2634940A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
| EP1801140A1 (en) | 2005-12-22 | 2007-06-27 | Mnemoscience GmbH | Macro-diacrylate |
| CA2646156C (en) * | 2006-03-22 | 2016-05-24 | Medigene Ag | Treatment of triple receptor negative breast cancer |
| ES2780193T3 (es) | 2006-07-12 | 2020-08-24 | Univ Tennessee Res Found | Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina |
| AU2007287070C1 (en) | 2006-08-24 | 2013-02-14 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
| KR101638035B1 (ko) | 2007-01-22 | 2016-07-11 | 지티엑스, 인코포레이티드 | 핵 수용체에 결합하는 물질 |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
| CA2886498C (en) | 2007-09-11 | 2017-09-26 | Gtx, Inc. | Solid forms of selective androgen receptor modulators |
| US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| EP2486149B1 (en) | 2009-08-06 | 2015-06-17 | John Wayne Cancer Institute | Diagnosis of primary and metastatic basal-like breast cancer and other cancer types |
| BR112012009262A2 (pt) | 2009-10-23 | 2019-09-24 | Health Research Inc | ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo |
| US8791158B2 (en) | 2010-01-11 | 2014-07-29 | Gtx, Inc. | Methods of treating meibomian gland dysfunction |
| UY33740A (es) * | 2010-11-18 | 2012-05-31 | Takeda Pharmaceutical | Método para tratar el cáncer de mama y cáncer de ovarios |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| EP3733170A1 (en) | 2012-07-13 | 2020-11-04 | Oncternal Therapeutics, Inc. | A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms) |
-
2013
- 2013-03-07 EP EP20179413.8A patent/EP3733170A1/en active Pending
- 2013-03-07 IN IN1046DEN2015 patent/IN2015DN01046A/en unknown
- 2013-03-07 DK DK13817231.7T patent/DK2872482T3/da active
- 2013-03-07 CN CN201711417639.XA patent/CN108143728A/zh active Pending
- 2013-03-07 HU HUE13817231A patent/HUE052574T2/hu unknown
- 2013-03-07 RU RU2015104780A patent/RU2648959C2/ru active
- 2013-03-07 HR HRP20201463TT patent/HRP20201463T1/hr unknown
- 2013-03-07 PT PT138172317T patent/PT2872482T/pt unknown
- 2013-03-07 AU AU2013203600A patent/AU2013203600C1/en active Active
- 2013-03-07 JP JP2015521597A patent/JP6226978B2/ja active Active
- 2013-03-07 LT LTEP13817231.7T patent/LT2872482T/lt unknown
- 2013-03-07 EP EP13817231.7A patent/EP2872482B1/en active Active
- 2013-03-07 CN CN201911188725.7A patent/CN110840870A/zh active Pending
- 2013-03-07 ES ES13817231T patent/ES2818915T3/es active Active
- 2013-03-07 US US13/789,005 patent/US9604916B2/en active Active
- 2013-03-07 KR KR1020157003951A patent/KR102122941B1/ko active Active
- 2013-03-07 WO PCT/US2013/029667 patent/WO2014011220A2/en not_active Ceased
- 2013-03-07 MX MX2015000572A patent/MX375256B/es active IP Right Grant
- 2013-03-07 PL PL13817231T patent/PL2872482T3/pl unknown
- 2013-03-07 CN CN201380040703.0A patent/CN104754939A/zh active Pending
- 2013-03-07 CA CA2879049A patent/CA2879049C/en active Active
- 2013-03-07 KR KR1020207016499A patent/KR102238970B1/ko active Active
- 2013-03-07 RU RU2017141776A patent/RU2717835C2/ru active
-
2015
- 2015-01-12 IL IL236681A patent/IL236681B/en active IP Right Grant
- 2015-01-13 MX MX2020009725A patent/MX2020009725A/es unknown
-
2016
- 2016-06-03 AU AU2016203696A patent/AU2016203696B2/en active Active
-
2017
- 2017-03-13 JP JP2017046924A patent/JP6386120B2/ja active Active
-
2018
- 2018-02-28 AU AU2018201450A patent/AU2018201450B2/en active Active
- 2018-08-08 JP JP2018149623A patent/JP6759290B2/ja active Active
-
2020
- 2020-09-09 CY CY20201100853T patent/CY1123542T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009725A (es) | Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms). | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MX2017004526A (es) | Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. | |
| PH12017500639A1 (en) | Neuroactive compounds and methods of use thereof | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| MX2016002826A (es) | Anticuerpos anti-b7-h1 para tratar tumores. | |
| MX2022001757A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer. | |
| MX370597B (es) | Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer. | |
| MX2016001901A (es) | Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno. | |
| SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| PH12016501672A1 (en) | Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia | |
| MX2018006477A (es) | Anticuerpos y metodos de uso de estos. | |
| MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| EP3552665A3 (en) | Antibodies | |
| MX2018014435A (es) | Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer. | |
| UY35493A (es) | Métodos para el tratamiento de la osteogénesis imperfecta | |
| MX380220B (es) | Composiciones farmacéuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofílica. | |
| IL240060A0 (en) | Treatment involving antibodies against claudin 2. 18 for the treatment of cancer | |
| MY184628A (en) | Afucosylated anti-fgfr2iiib antibodies | |
| GEP201706612B (en) | Methods for the treatment of breast cancer | |
| MX379621B (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer | |
| AR086390A1 (es) | Metodo para el tratamiento de malignidades solidas que incluyen malignidades solidas avanzadas o metastasicas | |
| SMT202200458T1 (it) | Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |